Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Caladrius Biosciences Inc
LSTA | US
4.01
USD-0.52
-11.48%
LSTA | US
Loading StockChartView...
About Caladrius Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
4.01
Open
4.50
High
4.65
Low
3.67
Lisata Therapeutics Inc. a clinical-stage pharmaceutical company focuses on the discovery development and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1 which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor including metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with a range of anti-cancer regimens; HONEDRA a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201 a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem Inc. and changed its name to Caladrius Biosciences Inc. in June 2015. The company was formerly known as Caladrius Biosciences Inc. and changed its name to Lisata Therapeutics Inc. on September 15 2022. Lisata Therapeutics Inc. was incorporated in 1980 and is headquartered in Basking Ridge New Jersey.
View LessLSTA | US
Risk
48.6
Sharpe
0.92
Luna's Score
39/100
Recommendation
Sell
Luna says (LSTA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
69.5%1 month
48.6%3 months
183.8%6 months
138.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.65
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.82
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.93M
MarketCap
33.36M
MarketCap(USD)
33.36M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-44.03
Short ratio
0.92
Short perc.
0.18
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.35
Range1M
1.38
Range3M
3.03
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
3.20
Price X volume
952.82K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.82 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.65 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 183.82 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 33.36M | 3.66B | Emerging |
